Anthrax Fusion Toxins with Improved Ability to Penetrate Cells

Available for licensing are novel conjugated or fusion proteins comprised of anthrax toxin lethal factor cytolethal distending toxin subunit B. Several human tumor cell lines have been found to be highly sensitive to these toxins with LD50 values in the pM range. In vivo studies in mice have revealed that these toxins selectively treat tumors and have very low systemic toxicity.

Potential Commercial Applications: Competitive Advantages:
  • Pharmaceutical compositions to selectively treat cancer
  • Applications to treat or prevent growth of undesirable cells
  • Selective with low systemic toxicity
  • Potent (pM LD50 values)

Stephen Leppla (NIAID)
Christopher Bachran (NIAID)

Intellectual Property:
US Application No. 61/837,428

Licensing Contact:
Patrick McCue , Ph.D.
NIH Office of Technology Transfer
Phone: 301-496-7057

OTT Reference No: E-120-2013/0

Updated: Aug-22-2013